By Vrushab Gowda
On September 13th, President Trump issued an executive order aimed at addressing ballooning pharmaceutical expenditures.
The order seeks to apply a “most favored nation” scheme to prescription drug payments made through Medicare Parts B and D, which are currently on track to exceed $130 billion. Although ambitious in scope, the order’s ultimate impact remains to be seen.